Table E-3. Quality and applicability table for KQ 3 studies—postdischarge treatment for UA/NSTEMI

| **Study** | **Intervention/Comparator** | **Study Quality** | **Limitations to Applicability** |
| --- | --- | --- | --- |
| Alexander, 2008108  CRUSADE | * Clopidogrel * No clopidogrel | Fair | * None |
| Aronow, 2008109  BRAVO | * ASA <162mg/day, maintenance dose: 100 mg * ASA >162 mg/day, maintenance dose: 325 mg | Good | * Study's cointerventions did not adequately reflect routine clinical practice (e.g., use of medical therapy for secondary prevention – antiplatelet agents, HTN/DM/lipid control) |
| Banerjee, 2011110 | * No PPI * PPI | Good | * None |
| Barada, 2008111 | * PPI * Placebo | Poor | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US * Study was conducted only at a single site |
| Bernardi, 2007112  RACS | * Dual therapy: clopidogrel 30 day + ASA * Dual therapy: clopidogrel 180 day + ASA | Fair | * Study conducted solely outside the US |
| Bhatt, 2010113  COGENT | * Omeprazole 20 mg * Placebo | Good | * None |
| Bhurke, 2012114 | * Clopidogrel + PPI * Clopidogrel | Fair | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate |
| Bonde, 2010115 | * Placebo * Clopidogrel | Fair | * Study conducted solely outside the US |
| Buresly, 2005116 | * ASA * Warfarin | Good | * Study conducted solely outside the US |
| Butler, 2009117 | * DES with clopidogrel intended duration ≤3 mo * DES with clopidogrel intended duration * 6 mo * BMS with clopidogrel intended duration ≤3 mo * BMS with clopidogrel intended duration 6 mo * DES with clopidogrel intended duration ≥12 mo * BMS with clopidogrel intended duration ≥12 mo | Fair | * Study conducted solely outside the US |
| Charlot, 2010118 | * No PPI * PPI * Placebo * Clopidogrel | Good | * None |
| Charlot, 2011119 | * PPI * No PPI | Good | * None |
| Charlot, 2012120 | * Clopidogrel up to 90 days * Clopidogrel >90 days | Fair | * Study did not report participants’ baseline characteristics |
| Cheng, 2010121  T-ACCORD Registry | * ASA * Clopidogrel * Dual therapy (ASA + clopidogrel) | Good | * Study conducted solely outside the US |
| Chitose, 2011122  KICS | * PPI * No PPI | Good | * None |
| Evanchan, 2010123 | * PPI * Placebo | Good | * Study exclusion criteria were poorly described or not appropriate * Study was conducted only at a single site |
| Fosbol, 2012124 | * ASA * Warfarin * ASA + clopidogrel * ASA + clopidogrel + warfarin | Fair | * None |
| Gao, 2009125 | * Omeprazole 40 mg loading, 20 mg maintenance | Poor | * Study did not report participants' baseline characteristics * Study did not report participants' comorbid conditions. * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Gaspar, 2010126 | * PPI * No PPI | Good | * None |
| Goodman, 2012127  Mahaffey, 2011128  Wallentin, 200982  PLATO | * PPI * Placebo | Good | * None |
| Gupta, 2010129 | * PPI * Placebo | Fair | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study was conducted only at a single site |
| Gwon, 2012130 | * ASA + clopidogrel 6 mo * ASA + clopidogrel 12 mo | Good | * Study conducted solely outside the US |
| Harjai, 2009131 | * ASA 81–325 mg/day + clopidogrel >12 mo (whole cohort any stent), Maintenance dose: ASA 81–325 mg/day + clopidogrel 75 mg/day or ticlopidine (dose not specified). * ASA 81–325 mg/day + clopidogrel ≤ 12 mo (whole cohort any stent), Maintenance dose: ASA 81–325 mg/day + clopidogrel 75 mg/day or ticlopidine (dose not specified). | Good | * None |
| Harjai, 2011132  GHOST | * ASA, maintenance dose: 81 mg/day * ASA, maintenance dose: 162-325 mg/day | Fair | * Study selectively recruited participants who demonstrated a history of favorable or unfavorable response to drug or other interventions for the condition. |
| Harjai, 2011133 | * PPI * No PPI | Good | * None |
| Ho, 2007134 | * Continued clopidogrel * Discontinued clopidogrel | Fair | * Population was almost entirely male. |
| Ho, 2009135 | * PPI * Placebo | Good | * None |
| Hsiao, 2011136 | * PPI * No PPI | Good | * None |
| Jang, 2011137 | * Warfarin * Placebo | Poor | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Juurlink, 2009138 | * Clopidogrel + nonfatal MI in 90 days * Clopidogrel | Good | * Study conducted solely outside the US |
| Karjalainen, 2007139 | * Warfarin * Placebo | Good | * Study conducted solely outside the US |
| Konstantino, 2006140 | * ASA + ticlopidine/ clopidogrel * ASA + ticlopidine/clopidogrel +warfarin | Fair | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Kreutz, 2010141 | * PPI * Placebo | Good | * Study eligibility criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Lamberts, 2013142 | * Clopidogrel + ASA   Clopidogrel + ASA + oral anticoagulant | Good | * Study conducted solely outside the US |
| Lim, 2005143 | * ASA * ASA + clopidogrel | Fair | * Groups were significantly different with respect to in hospital revascularization procedures. * Statistical comparison of the results not reported. * In hospital antithrombotic management and bleeding events not reported. |
| Lopes, 2010144 | * Warfarin * Placebo | Good | * None |
| Maegdefessel, 2008145 | * Clopidogrel | Fair | * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US * Study was conducted only at a single site |
| Ng, 2008146 | * PPI * Placebo | Good | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Ng, 2011147 | * Esomeprazole 20 mg * Famotidine 40 mg | Good | * Study conducted solely outside the US * Study was conducted only at a single site |
| Nguyen, 2007148  GRACE | * ASA + thienopyridine * ASA or thienopyridine | Good | * None |
| O’Donoghue, 2009149  TRITON-TIMI 38 | * PPI * No PPI | Good | * None |
| Ortolani, 2011150 | * PPI * No PPI | Good | * None |
| Pekdemir, 2003151 | * 1 mo ASA 100 mg/day + clopidogrel 75 mg/day   Loading dose: 300 mg clopidogrel + 300 mg ASA + 10,000 IU heparin IV intraoperative  Maintenance dose: 75 mg/day clopidogrel + 100 mg/day ASA   * 6 mo ASA 100 mg/day + clopidogrel 75 mg/day   Loading dose: 300 mg clopidogrel + 300 mg ASA + 10,000 IU heparin IV intraoperative  Maintenance dose: 75 mg/day clopidogrel + 100 mg/day ASA | Fair | * Study conducted solely outside the US * Study was conducted only at a single site |
| Persson, 2011152  RIKS-HIA and SCAAR | * Warfarin * Placebo | Good | * Study conducted solely outside the US |
| Quinn, 2004153  Gusto IIb and PURSUIT | * ASA maintenance dose <150mg * ASA maintenance dose ≥150mg | Good | * None |
| Rassen, 2009154 | * PPI * Placebo | Good | * None |
| Ray, 2010155 | * PPI * Placebo | Good | * None |
| Ren, 2011156 | * Omeprazole 20 mg * Placebo | Poor | * Study did not report participants' comorbid conditions. * Study conducted solely outside the US |
| Rossini, 2008157 | * Clopidogrel + ASA + Warfarin * Clopidogrel + ASA | Good | * Study conducted solely outside the US |
| Rossini, 2011158 | * PPI * No PPI | Good | * None |
| Roy, 2009159 | * Clopidogrel loading dose 300mg * Clopidogrel loading dose 600mg | Poor | * Study was conducted only at a single site |
| Ruiz-Nodar, 2008160 | * Warfarin * ASA | Good | * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Ruiz-Nodar, 2012161 | * Warfarin * No oral anticoagulant | Fair | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Sarafoff, 2010162 | * PPI * Placebo | Good | * None |
| Schmidt, 2012163 | * Clopidogrel 75 mg maintenance dose * PPI | Poor | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Schulz, 2009164 | * Clopidogrel + ASA   Loading dose: 600 mg clopidogrel + 500 mg ASA  Maintenance dose: 75mg clopidogrel daily + ASA 100 mg twice daily | Fair | * Study conducted solely outside the US |
| Sibbald, 2010165 | * Early clopidogrel in-hospital * No early clopidogrel in-hospital | Good | * None |
| Simon, 2011166  FAST-MI | * PPI * Placebo | Good | * None |
| So, 2009167 | * Clopidogrel * Placebo | Fair | * Study conducted solely outside the US * Study was conducted only at a single site |
| Steinhubl, 2002168  CREDO | * Clopidogrel 1 mo * Clopidogrel 12 mo | Good | * None |
| Stenestrand, 2005169  RIKS-HIA | * ASA * Oral anticoagulant | Good | * Study conducted solely outside the US |
| Stockl, 2010170 | * PPI * Placebo | Good | * None |
| Tentzeris, 2010171 | * PPI * No PPI | Good | * None |
| Tsai, 2011172 | * Clopidogrel + PPI * Clopidogrel | Good | * None |
| Valgimigli, 2012173  PRODIGY | * Clopidogrel   Loading dose: 300 or 600 mg  Maintenance dose: 75 mg  Duration 6 mo   * Clopidogrel   Loading dose: 300 or 600 mg  Maintenance dose: 75 mg  Duration 24 mo | Good | * Study conducted solely outside the US |
| Valkhoff, 2011174 | * PPI * Placebo | Poor | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Comparator(s) not well described * Study conducted solely outside the US * Study was conducted only at a single site |
| van Boxel, 2010175 | * Clopidogrel + PPI * Clopidogrel | Fair | * Study eligibility criteria were poorly described or not appropriate * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Wu, 2010176 | * PPI * Placebo | Good | * Study exclusion criteria were poorly described or not appropriate * Study conducted solely outside the US |
| Yusuf, 2001177  Peters, 2003178  CURE | * Clopidogrel 300 mg loading dose, 75 mg daily * Placebo | Good | * None |
| Zairis, 2010179 | * Omeprazole * Placebo | Good | * Study conducted solely outside the US * Study was conducted only at a single site |
| Zeymer, 2008180  ACOS Registry | * ASA + clopidogrel * ASA | Poor | * Study exclusion criteria were poorly described or not appropriate * Diagnostic or therapeutic advances have been made in routine practice since the study was conducted * Revascularization as well as postdischarge medications are poorly described * Use of substandard alternative therapy (e.g., standard of treatment not from current practice) |

Abbreviations: ACT=activated clotting time; ASA=aspirin; BMS=bare metal stent;DES=drug-eluting stent; DM=diabetes mellitus; HTN=hypertension; IU=international units; IV=intravenous; mg=milligram/milligrams; MI=myocardial infarction; mo=month/months; PPI=proton pump inhibitor; sec=second/seconds